Novo Nordisk | NVO

Stock Price
55.22
Daily Change
-0.93 -1.66%
Monthly
21.68%
Yearly
-57.89%
Q3 Forecast
54.42

Peers Price Chg Day Year Date
Aurora Cannabis 6.78 0.09 1.35% -7.50% Sep/05
ANI Pharmaceuticals 95.35 -0.65 -0.68% 57.58% Sep/05
Bristol-Myers Squibb 47.26 0.12 0.25% -2.58% Sep/08
Corcept Therapeutics 69.36 -0.01 -0.01% 101.75% Sep/05
GlaxoSmithKline 1,466.25 -9.75 -0.66% -11.86% Sep/08
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
Merck 84.71 0.66 0.79% -28.14% Sep/05
Novartis 102.62 -1.36 -1.31% 3.03% Sep/08
Novo Nordisk A/S 345.50 -4.50 -1.29% -61.05% Sep/08
Novo Nordisk 55.22 -0.93 -1.66% -57.89% Sep/05
Prestige Brands 65.05 -1.70 -2.55% -12.50% Sep/05
Pacira 26.45 -0.28 -1.05% 90.97% Sep/05
Perrigo 22.65 -0.64 -2.75% -20.79% Sep/05
Drreddys Laboratories 14.34 0.19 1.34% -81.89% Sep/05
Sanofi 79.22 -0.28 -0.35% -25.09% Sep/08
Supernus Pharmaceuticals 46.00 0.57 1.25% 35.93% Sep/05
Bausch Health Companies 10.18 0.20 2.00% 20.90% Sep/05
Canopy Growth 2.02 0.11 5.76% -66.72% Sep/05
Zoetis 153.32 0.12 0.08% -19.13% Sep/05


Novo Nordisk traded at $55.22 this Friday September 5th, decreasing $0.93 or 1.66 percent since the previous trading session. Looking back, over the last four weeks, Novo Nordisk lost 21.68 percent. Over the last 12 months, its price fell by 57.89 percent. Looking ahead, we forecast Novo Nordisk to be priced at 54.42 by the end of this quarter and at 52.09 in one year, according to Trading Economics global macro models projections and analysts expectations.

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.